Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab in the treatment of patients with MM.
Saad Z. Usmani, M.D on DARZALEX FASPRO: How Does This Help? @LevineCancer @szusmani
